

SEP 25 1997

BLACKSTONE MEDICAL, INC.
90 Brookdale Drive
Springfield, MA 01104

Premarket Notification
BLACKSTONE MEDICAL, INC.
Laparoscopic Disc Removal System
Confidential

K972768

510 (k) Summary
BLACKSTONE MEDICAL, INC.
Laparoscopic Disc Removal System

This summary is provided in accordance with the Safe Medical Devices Act of 1990 (SMDA). The information provided in the 510 (k), Premarket Notification, was in accordance with 21 CFR 807.87.

The BLACKSTONE MEDICAL, INC. Laparoscopic Disc Removal System is an assortment of surgical instruments utilized in minimally invasive Laparoscopic lumbar discectomy surgical procedures.

The conclusion that the BLACKSTONE MEDICAL, INC. Laparoscopic Disc Removal System is substantially equivalent to legally marketed predicate systems was reached through consideration of the requirements of substantial equivalence determinations. These requirements are set forth in the document, published on June 30, 1986 by the Center for Devices and Radiological Health (CDRH), entitled "Guidance on the Center for Devices and Radiological Health's Premarket Notification Review Program."

The new disc removal tools and introduction instruments contain substantially equivalent technology and materials as the predicate disc removal tools utilized in both the Surgical Dynamics, Inc. Working Channel Scope and Instrument Set, and the Blackstone Medical Inc. Nucleus Pulposus Evacuator System.

Based on the reasons provided, the BLACKSTONE MEDICAL, INC. Laparoscopic Disc Removal System is substantially equivalent to legally marketed predicate minimally invasive Laparoscopic lumbar discectomy surgical instruments.



SEP 25 1997

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20856

Mr. Joseph S. Mooney
Blackstone Medical, Inc.
90 Brookdale Drive
Springfield, Massachusetts 01104

Re: K972768
Trade Name: BLACKSTONE MEDICAL, INC. Laparoscopic Disc Removal System
Regulatory Class: II
Product Code: HRX
Dated: July 22, 1997
Received: July 24, 1997

Dear Mr. Mooney:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "C. Witten", with a stylized flourish at the end.

Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

